Clinical Trial Update: Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Idelalisib (idelalisib)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2017-03-31